Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 30, 2020 07:00 ET | Source: Neon Therapeutics, Inc.

Neon Therapeutics Announces Acceptance of European Clinical Trial Authorization Application for NEO-PTC-01

CAMBRIDGE, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN) today announced the acceptance of its Clinical Trial Authorization (CTA) from the Dutch Health Authority...
March 02, 2020 07:00 ET | Source: Neon Therapeutics, Inc.

Neon Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

CAMBRIDGE, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN) today reported financial results for the fourth quarter and full-year ended December 31, 2019 and provided...
January 16, 2020 07:30 ET | Source: Neon Therapeutics, Inc.

BioNTech to acquire Neon to strengthen global leadership position in T cell therapies

Further expands BioNTech’s growing CAR-T and TCR therapy pipeline through addition of neoantigen specific cell therapies, including a T cell therapy targeting shared RAS oncogenesAccelerates...
December 18, 2019 08:01 ET | Source: Neon Therapeutics, Inc.

Neon Therapeutics Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01

CAMBRIDGE, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN) today announced that it has filed a Clinical Trial Authorization (CTA) with the Dutch Health Authority for...
November 20, 2019 16:05 ET | Source: Neon Therapeutics, Inc.

Neon Therapeutics Announces New Strategic Focus on Novel T Cell Programs

Lead program, NEO-PTC-01, is a personalized neoantigen adoptive T cell therapy candidate to address refractory solid tumors Corporate restructuring effected to focus resources while exploring...
November 12, 2019 07:00 ET | Source: Neon Therapeutics, Inc.

Neon Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights

CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today reported...
November 08, 2019 07:00 ET | Source: Neon Therapeutics, Inc.

Neon Therapeutics Announces Updated Data Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Updated Results from NT-001 Trial of NEO-PV-01 Demonstrate Prolonged Progression-Free and Overall Survival vs. Historical Benchmark Data Advanced Process Development Supports Clinical Trial...
September 05, 2019 16:01 ET | Source: Neon Therapeutics, Inc.

Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens

Proprietary class II prediction tool achieved up to a 61-fold improvement in predicting MHC class II peptides compared to standard methods Proprietary capabilities to be integrated into Neon’s RECON®...
August 06, 2019 07:00 ET | Source: Neon Therapeutics, Inc.

Neon Therapeutics Reports Second Quarter 2019 Financial Results

Planning to present more detailed data from NT-001 clinical trial evaluating NEO-PV-01 in advanced or metastatic melanoma, non-small cell lung and bladder cancers at an upcoming medical society...
July 15, 2019 06:00 ET | Source: Neon Therapeutics, Inc.

Neon Therapeutics’ Personal Neoantigen Vaccine Study Demonstrates Prolonged Progression-Free Survival in Advanced or Metastatic Melanoma, Non-Small Cell Lung and Bladder Cancers

NEO-PV-01, in combination with OPDIVO® (nivolumab), broadens the immune response to specific new cancer targets, leading to the first demonstration of improved clinical durability for a personal...